NCT03890861 Reducing African Americans' Alzheimer's Disease Risk Through Exercise (RAATE)"
| NCT ID | NCT03890861 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Pennington Biomedical Research Center |
| Condition | Dementia, Alzheimer Type |
| Study Type | INTERVENTIONAL |
| Enrollment | 125 participants |
| Start Date | 2019-08-09 |
| Primary Completion | 2025-11 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 125 participants in total. It began in 2019-08-09 with a primary completion date of 2025-11.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The RAATE proposal is designed to determine the effects of physical activity on risk factors for Alzheimer's Disease in older African American adults. The study will compare a physical activity program to an active control group. There are three main objectives of the protocol: 1) to determine if a physical activity intervention tailored to older African American adults is effective in modifying cognitive function associated with Alzheimer's Disease, 2) to determine if a physical activity intervention tailored to older African American adults is effective in modifying brain function and structure associated with Alzheimer's Disease, and 3) to determine if a physical activity promotion intervention tailored to African American adults is effective at enhancing physiological parameters. The primary endpoints for the study are episodic memory and executive functioning. The secondary outcomes include anthropometry, blood pressure, brain activation, cerebral blood flow, volume of whole brain and white matter hyperintensities, cardiorespiratory fitness, objectively measured physical activity, circulating hormones, and telomere length.
Eligibility Criteria
Inclusion Criteria: 1. self- identify as African American 2. 60 years and older 3. willing to accept randomization 4. willing to attend group sessions 5. lacking plans to move during the study period 6. free of conditions that would make regular exercise unsafe (e.g. uncontrolled asthma, severe sickle cell disease, etc.) 7. not engaged in regular physical activity 8. Short Physical Performance Battery score \>/= 4 9. physically capable of exercise, Exclusion Criteria: 1. cognitive impairment that would interfere with participating in group interactions 2. unwilling to give written informed consent 3. inability to attend group sessions 4. conditions that prevent regular exercise 5. conditions that the medical or principal investigator determine to warrant exclusion
Contact & Investigator
Robert L Newton, Jr., PhD
PRINCIPAL INVESTIGATOR
Pennington Biomedical Research Center
Frequently Asked Questions
Who can join the NCT03890861 clinical trial?
This trial is open to participants of all sexes, aged 60 Years or older, studying Dementia, Alzheimer Type. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03890861 currently recruiting?
Yes, NCT03890861 is actively recruiting participants. Contact the research team at Melissa.Harris@pbrc.edu for enrollment information.
Where is the NCT03890861 trial being conducted?
This trial is being conducted at Baton Rouge, United States.
Who is sponsoring the NCT03890861 clinical trial?
NCT03890861 is sponsored by Pennington Biomedical Research Center. The principal investigator is Robert L Newton, Jr., PhD at Pennington Biomedical Research Center. The trial plans to enroll 125 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.